Evaluation of the Efficacy of a Turmeric Extract (Arantal®) in Patients With Osteoarthritis of the Knee (Gonarthrosis).

Phase 2

Completed

• Conditions: Osteoarthritis, Knee
• Interventions: Dietary Supplement: Arantal® (highly bioavailable turmeric extract)

• Registration Number: NCT00992004
• Lead Sponsor: Bioxtract SA

Brief Summary

The purpose of this study is to determine the efficacy and the tolerance on 15 days of a turmeric extract (Arantal®) on pain related to gonarthrosis.

Detailed Description

Not available

Study Timeline

• Study Start: 2009-06
• Study First Submitted: 2009-10-07
• Study First Submitted QC: 2009-10-07
• Study First Posted: 2009-10-08
• Status Verified: 2010-05
• Primary Completion: 2010-05
• Study Completion: 2010-05
• Last Update Submitted: 2010-05-06
• Last Update Posted: 2010-05-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 280

Inclusion Criteria

• Patient is 40 through 80 years of age
• Subject diagnosed with femorotibial osteoarthritis of the knee (diagnosed according to the clinical and radiologic criteria of ACR),
• Patient's Assessment of Arthritis Pain measurement on the last 24 hours of at least 50 mm on VAS,
• Patient has not received any NSAIDs within 72 hours and any analgesics within 24 hours,
• Patients with chronic knee pain (i.e., knee pain at least every other day during the month preceding inclusion),
• Patients with radiologic knee osteoarthritis (Kellgren-Lawrence grade 2-4, on radiography less than 12 months old),
• Patients having signed the informed consent,
• Patients capable of comprehend the study instructions.

Exclusion Criteria

• Related to the osteoarthritis pathology:

  • Osteoarthritis linked to a metabolic arthropathy: chondrocalcinosis already diagnosed or defined by calcium edging on at least one femorotibial joint space, gout...,
  • Predominant associated symptomatic femoropatellar osteoarthritis,
  • Chondromatosis or villonodular synovitis of the knee,
  • Recent trauma (< 1 month) of the knee responsible for the pain,
  • Knee joint effusion justifying an evacuation through puncturing,
  • Inflammatory flare (night pain, joint effusion) corresponding to a KOFUS score less than 7,
  • Pathology potentially interfering with the evaluation (metabolic inflammatory arthropathy, rheumatoid arthritis, lower limb radiculalgia, arthritis...),

• Related to previous and associated treatments:

  • Corticosteroids injection in the previous month, whatever the joint concerned,
  • Hyaluronan injection in the evaluated knee during the previous 6 months,
  • Patient who took NSAID in the 72 hours prior to inclusion or Analgesics in the 24 hours prior to inclusion,
  • Slow-acting drugs for OA and/or dietary supplements taken within less than 3 months prior to the study product administration or for which the dose has been modified in the last three months (ex: chondroitin sulfate, diacerein, soy and avocado unsaponifiables, oxaceprol, granions de cuivre, glucosamine, phytotherapy for OA, homeopathy for OA...),
  • Anticoagulant treatment without gastric protection,
  • General corticotherapy,
  • Contraindication to paracetamol.

• Related to associated pathologies:

  • Patient suffering from serious associated illness (liver failure, kidney failure, non-controlled cardiovascular diseases...),
  • Peptic ulcer.

• Related to patients:

  • Pregnant or breastfeeding women
  • Pre-menopausal women with no contraception
  • Patients unable to write
  • Patients enrolled in a clinical trial in the previous 3 months
  • Patients under juristic protection or under guardianship.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Arantal®	Arantal® (highly bioavailable turmeric extract)	Highly bioavailable turmeric extract (food supplement)
Placebo	Arantal® (highly bioavailable turmeric extract)	Same capsule without the active ingredients (only excipients)

Primary Outcome Measures

Name	Time	Method
Patient's Assessment of Arthritis Pain using a Visual Analogue Scale (OA-Pain VAS)	15 days

Secondary Outcome Measures

Name	Time	Method
Kinetics of the analgesic effect by a variance analysis in repeated measures (Likert Scale)	15 days

Trial Locations

Locations (1)

Henri Mondor Hospital; 🇫🇷 Creteil, France